Metabolic & Weight

Survodutide Dosing & Reconstitution Calculator

Dual glucagon/GLP-1 receptor agonist for metabolic disease and NASH.

TL;DR - Survodutide is a metabolic & weight peptide with a typical starting dose of 2.4 mg. For a 5 mg vial, add 1 mL bacteriostatic water to yield 5 mg/mL.
2.4 mg
Start Dose
5 mg
Vial
1 mL
BAC Water
5
mg/mL
2.4 mg draw on a 100-unit insulin syringe
010203040506070809010048 IUascendpeptide.org
Compare Similar
This Peptide
Survodutide
2.4 mg start
Retatrutide
0.5 mg start
Coming soon
Tirzepatide
2.5 mg start
Coming soon
Track Survodutide in Protocol Tracker
Frequently Asked
How do I reconstitute Survodutide?
Add 1 mL of bacteriostatic water to a 5 mg vial, injecting slowly down the inside wall. Swirl gently; never shake. This yields a concentration of 5 mg/mL.
What is the recommended dose of Survodutide?
A typical research dose is 2.4 mg. Consult the ASCEND calculator for your specific vial concentration and draw volume.
How many doses are in a Survodutide vial?
A 5 mg vial reconstituted with 1 mL BAC water yields approximately 2 doses at 2.4 mg each.
How many IU is 2.4 mg of Survodutide on a syringe?
With a 5 mg vial reconstituted in 1 mL bacteriostatic water, the concentration is 5 mg/mL. For a 2.4 mg dose: Volume = 2.4 mg ÷ 5 mg/mL = 0.48 mL. Draw to the 48 line on a 100-unit insulin syringe. You can adjust these values in the ASCEND calculator for any vial size.
What does a Survodutide dosage calculator do?
A Survodutide dosage calculator converts your vial size and BAC water volume into an exact syringe draw in IU. Enter your vial strength (5 mg), reconstitution volume (1 mL), and target dose to get the precise line to draw on an insulin syringe.
What is the Survodutide reconstitution calculator formula?
Draw volume (mL) = Dose (mg) divided by Concentration (mg/mL). For a 5 mg vial with 1 mL BAC water: concentration = 5 mg/mL. For a 2.4 mg dose, the ASCEND calculator gives the exact IU line on your syringe instantly.
Peptide Intelligence
What receptors does Survodutide target?
Survodutide is a dual glucagon/GLP-1 receptor agonist. Glucagon receptor activation drives hepatic fat clearance and energy expenditure, making it particularly relevant for NASH/MASH research alongside metabolic weight management.
What is the half-life of Survodutide?
Survodutide has a half-life supporting once-weekly dosing, estimated at approximately 5–7 days based on phase 2 pharmacokinetic data. Dose escalation over several months is standard in research protocols.
How does Survodutide compare to GLP-1 mono-agonists for liver fat?
Survodutide showed superior liver fat reduction versus GLP-1 mono-agonists in NASH trials. Phase 2 data showed greater than 50% liver fat reduction in a majority of subjects at maximal doses, attributed to glucagon receptor-driven hepatic fat oxidation.
Primary Sources
ClinicalTrials NASH Trial NCT04771273
Data last reviewed 2026-06-03 · Methodology →
Cite This Calculator